NeuralSense
NeuralSense Raises $200M Series C to Transform Biotech
Quick Facts
NeuralSense Raises $200M Series C in Latest Funding Round
NeuralSense has successfully closed a $200M Series C funding round, marking a significant milestone in the company's growth trajectory. The round was led by Founders Fund, with participation from General Catalyst.
Company Overview
Founded in 2021 and headquartered in Austin, TX, NeuralSense has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses
With a current valuation of $800M, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $200M Series C
- Valuation: $800M
- Lead Investor: Founders Fund
Future Outlook
As NeuralSense moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
PrimeNet Raises $300M Series C to Transform Biotech
PrimeNet has secured $300M Series C in funding to accelerate growth and innovation. Leading machine learning platform automating enterprise workflows with advanced AI models...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...